耗尽化学反应性线粒体裂变媒介DRP1并不能减轻肉瘤耐药性的影响
Karolina Borankova1,2, Matyas Solny1, Maria Krchniakova1
1Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic.
Life science alliance
|December 6, 2024
概括
向线粒体分裂蛋白DRP1不会影响儿科肉瘤的耐药性. 像AMPKα1这样的替代DRP1独立机制和调节剂可能在线粒体动力学和癌症进展中发挥作用.
科学领域:
- 细胞生物学 细胞生物学
- 癌症研究 癌症研究
- 线粒体动力学的动力学
背景情况:
- 线粒体动力学与癌症药物耐药性有关.
- 线粒体分裂/融合蛋白在儿科瘤中的作用尚不清楚.
研究的目的:
- 研究DRP1在多抗药性儿科瘤中的作用.
- 探索线粒体裂变的其他机制.
主要方法:
- 稳定的DRP1在拉布地肌肉瘤和骨髓瘤细胞中被淘汰.
- 评估药物耐药性,生长速度和线粒体形态.
- 分析了裂变适配器 (MFF,FIS1) 和AMPKα1.1.的表达.
主要成果:
- DRP1的淘汰并没有改变耐药性,生长或线粒体网络.
- 多年框架和FIS1的上调表明DRP1独立的裂变.
- 降低AMPKα1水平并没有影响化学敏感性.
结论:
- DRP1并没有直接参与儿科肉瘤的耐药性.
- 可能涉及线粒体动态的非正规调节者.
- 需要进一步的研究来描述这些替代途径.
相关概念视频
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
Drugs that Destabilize Microtubules
1.9K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
1.9K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K


